Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rofecoxib

FDA-approved product (tablet, oral), marketed as Vioxx.

Registered studies
32
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Rofecoxib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Rheumatic disease

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Coxibs
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA33.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae14.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rofecoxib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rofecoxib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Rofecoxib and Prolonged Constant Infusion of Gemcitabine in the Polychemotherapy Treatment of Advanced NSCLC

    NCT00385606 · start 2003-01

    Registered record
    Registry ID
    NCT00385606
    Conditions
    Advanced Non-small Cell Lung Cancer
    Interventions
    gemcitabine; prolonged continuous infusion gemcitabine; cisplatin; rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2003-01
    Completion
    2006-07
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Non-small Cell Lung Cancer
    Interventiongemcitabine; prolonged continuous infusion gemcitabine; cisplatin; rofecoxib
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Rofecoxib and Bupivacaine to Prevent Pain After Third Molar (Wisdom Tooth) Extraction

    NCT00050362 · start 2002-12

    Registered record
    Registry ID
    NCT00050362
    Conditions
    Pain; Tooth Extraction
    Interventions
    Rofecoxib and Bupivacaine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-12
    Completion
    2004-10
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain; Tooth Extraction
    InterventionRofecoxib and Bupivacaine
    PhasePhase 2
    Registry statusCompleted

  • A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

    NCT00140894 · start 2002-08-06

    Registered record
    Registry ID
    NCT00140894
    Conditions
    Adenomatous Polyposis Coli
    Interventions
    MK0966; rofecoxib / Duration of Treatment: 24 weeks; Comparator: placebo / Duration of Treatment: 24 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2002-08-06
    Completion
    2004-10-11
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomatous Polyposis Coli
    InterventionMK0966; rofecoxib / Duration of Treatment: 24 weeks; Comparator: placebo / Duration of Treatment: 24 weeks
    PhasePhase 4
    Registry statusTerminated

  • A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)

    NCT00092339 · start 2002-08-01

    Registered record
    Registry ID
    NCT00092339
    Conditions
    Postoperative Pain
    Interventions
    MK0966, rofecoxib; Comparator: valdecoxib, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-08-01
    Completion
    2002-09-15
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionMK0966, rofecoxib; Comparator: valdecoxib, placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)

    NCT00092313 · start 2002-06

    Registered record
    Registry ID
    NCT00092313
    Conditions
    Postoperative Pain
    Interventions
    MK0966, rofecoxib; Comparator: oxycodone and acetaminophen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-06
    Completion
    2002-09
    Enrolment
    271

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionMK0966, rofecoxib; Comparator: oxycodone and acetaminophen
    PhasePhase 3
    Registry statusCompleted

  • A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)

    NCT00092326 · start 2002-06

    Registered record
    Registry ID
    NCT00092326
    Conditions
    Postoperative Pain
    Interventions
    MK0966, rofecoxib; Comparator: oxycodone with acetaminophen, placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-06
    Completion
    2002-09
    Enrolment
    269

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionMK0966, rofecoxib; Comparator: oxycodone with acetaminophen, placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)

    NCT00092300 · start 2002-05

    Registered record
    Registry ID
    NCT00092300
    Conditions
    Postoperative Pain
    Interventions
    MK0966, rofecoxib; Comparator: valdecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-05
    Completion
    Not recorded
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain
    InterventionMK0966, rofecoxib; Comparator: valdecoxib
    PhasePhase 3
    Registry statusCompleted

  • Barrett's Esophagus - 315 - 3 Way Cross Over

    NCT00637988 · start 2002-04

    Registered record
    Registry ID
    NCT00637988
    Conditions
    Barrett's Esophagus
    Interventions
    Esomeprazole; Aspirin; Rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-04
    Completion
    2003-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBarrett's Esophagus
    InterventionEsomeprazole; Aspirin; Rofecoxib
    PhasePhase 4
    Registry statusCompleted

  • Effect of Rofecoxib and a Narcotic Analgesic to Treat Pain Following Arthroscopic Surgery (0966-179)(COMPLETED)

    NCT00390260 · start 2002-02

    Registered record
    Registry ID
    NCT00390260
    Conditions
    Pain, Postoperative Arthroscopy
    Interventions
    MK0966 / Duration of Treatment: 1 Days; Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days; Comparator: placebo (unspecified) / Duration of Treatment: 1 Days
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-02
    Completion
    2003-02
    Enrolment
    420

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain, Postoperative Arthroscopy
    InterventionMK0966 / Duration of Treatment: 1 Days; Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days; Comparator: placebo (unspecified) / Duration of Treatment: 1 Days
    PhasePhase 3
    Registry statusCompleted

  • Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction

    NCT00026819 · start 2001-11

    Registered record
    Registry ID
    NCT00026819
    Conditions
    Pain
    Interventions
    Rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-11
    Completion
    2003-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPain
    InterventionRofecoxib
    PhasePhase 2
    Registry statusCompleted

  • Study of Vioxx and Radiation Therapy for Brainstem Glioma

    NCT00038389 · start 2001-10

    Registered record
    Registry ID
    NCT00038389
    Conditions
    Glioma; Brain Neoplasms
    Interventions
    Vioxx
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2001-10
    Completion
    2005-01
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma; Brain Neoplasms
    InterventionVioxx
    PhasePhase 1
    Registry statusTerminated

  • Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

    NCT00031863 · start 2001-02

    Registered record
    Registry ID
    NCT00031863
    Conditions
    Colorectal Cancer
    Interventions
    rofecoxib; adjuvant therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-02
    Completion
    2007-09
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    Interventionrofecoxib; adjuvant therapy
    PhasePhase 3
    Registry statusCompleted

  • Safety of Lumiracoxib in Patients With Osteoarthritis

    NCT00637949 · start 2000-12

    Registered record
    Registry ID
    NCT00637949
    Conditions
    Osteoarthritis
    Interventions
    lumiracoxib; rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-12
    Completion
    2001-03
    Enrolment
    309

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis
    Interventionlumiracoxib; rofecoxib
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

    NCT00282386 · start 1999-12-23

    Registered record
    Registry ID
    NCT00282386
    Conditions
    Colorectal Adenoma
    Interventions
    MK0966; Rofecoxib / Duration of Treatment: 156 weeks; Placebo/ Duration of Treatment: 156 weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-12-23
    Completion
    2004-09-01
    Enrolment
    2,586

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Adenoma
    InterventionMK0966; Rofecoxib / Duration of Treatment: 156 weeks; Placebo/ Duration of Treatment: 156 weeks
    PhasePhase 3
    Registry statusCompleted

  • A Four-Week Study Comparing Acetaminophen Extended Release and Rofecoxib in the Treatment of Osteoarthritis of the Knee

    NCT00568295 · start 1999-10

    Registered record
    Registry ID
    NCT00568295
    Conditions
    Osteoarthritis of the Knee
    Interventions
    acetaminophen; Rofecoxib; Rofecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-10
    Completion
    2000-10
    Enrolment
    403

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoarthritis of the Knee
    Interventionacetaminophen; Rofecoxib; Rofecoxib
    PhasePhase 3
    Registry statusCompleted